Skip to main content

Antithrombotic Therapy

For the reconstructive urologist, perioperative antithrombotic management is a single decision balanced on two axes: the patient's thrombotic risk (baseline VTE risk, chronic anticoagulation indication, stent or arrhythmia status) and the procedure's bleeding risk (pelvic cancer surgery vs cystoscopy). Get the balance wrong in either direction and the consequences are severe — a postoperative PE after ureteral reimplantation or a hemorrhagic catastrophe after cystectomy on bridged warfarin. This article consolidates procedure-specific VTE risk estimates from the Tikkinen series, the AUA / EAU / ACCP prophylaxis recommendations, chronic-anticoagulant bridging and reversal, antiplatelet management around pelvic surgery, and the niche but important topic of antithrombin concentrate for heparin resistance — the drug-specific content the internist will ask a urologist about after an intraoperative ACT problem on bypass-assisted IVC thrombectomy.

See also: ERAS, Pulmonary Embolism, Cardiovascular Risk.

VTE Risk in Urologic Surgery​

Procedure-specific VTE risk in urology was systematically mapped by Tikkinen and the AUA Best Practice Statement collaborators in a 2018 series that remains the evidence reference for GU-specific prophylaxis decisions.[1][2]

Procedure-Specific 4-Week VTE Risk (Without Extended Prophylaxis)​

ProcedureVTE risk (symptomatic, 4 wk)
Radical cystectomy3–10%
Open radical prostatectomy1–2%
Robotic radical prostatectomy<0.5%
Open radical nephrectomy1–3%
Robotic/laparoscopic nephrectomy<1%
Partial nephrectomy (MIS)<1%
Pelvic floor / incontinence surgery<0.5%
Ureteral reconstruction<1%
Scrotal / penile surgery<0.2%
Urethroplasty (bulbar/penile)<0.5%
Cystoscopy / TURP / TURBT<0.5%

Patient-Level Risk Factors​

  • Prior VTE (single strongest predictor)
  • Active cancer — particularly pelvic oncology
  • Age >60
  • BMI ≥30
  • Prolonged immobility
  • Known thrombophilia (factor V Leiden, prothrombin G20210A, antithrombin deficiency, protein C/S deficiency, antiphospholipid syndrome)
  • Hormone therapy (including testosterone)
  • Indwelling central venous catheter
  • Prolonged operative time (>3–4 h)
  • Radiation field — prior pelvic RT increases both VTE risk and bleeding risk

Risk Stratification Tools​

Caprini score is the most widely used validated tool for general surgery and remains the default in AUA urologic practice:[2]

Caprini scoreRisk categoryRecommended prophylaxis
0–1Very lowEarly ambulation
2LowMechanical prophylaxis
3–4ModerateMechanical + chemical
≥5HighMechanical + chemical; consider extended

Pharmacologic Prophylaxis​

Agents​

AgentDoseNotes
Enoxaparin (LMWH)40 mg SC daily (30 mg SC q12h in high-risk or obese)First-line; 12 h before / 12 h after neuraxial
Dalteparin (LMWH)5,000 U SC dailyAlternative LMWH
Unfractionated heparin5,000 U SC q8–12 hCrCl <30 mL/min; short-acting; reversible with protamine
Fondaparinux2.5 mg SC dailyUse if HIT history; avoid CrCl <30
Apixaban / rivaroxaban2.5 mg BID / 10 mg dailyExtended oral prophylaxis in selected ortho/onc populations

Timing Around Neuraxial Anesthesia​

Regional anesthesia timing is a common point of error:

  • Prophylactic LMWH: hold ≥12 h before neuraxial placement / catheter removal.
  • Therapeutic LMWH: hold ≥24 h.
  • UFH prophylactic: no hold required before single-shot; hold 4–6 h with aPTT check for catheters.
  • Fondaparinux: avoid with indwelling catheters.

Extended (4-Week) Prophylaxis for Pelvic Oncology​

Radical cystectomy, open radical prostatectomy with PLND, and major pelvic oncologic reconstruction carry sufficient 30-day VTE risk to warrant LMWH continued for 28 days post-discharge — endorsed by the AUA Best Practice Statement and multiple international guidelines.[1][2][3] The absolute VTE reduction in pelvic cancer surgery is of the order of 2–4 percentage points at 30 days, with a small absolute increase in bleeding.

Mechanical Prophylaxis​

  • Intermittent pneumatic compression (IPC) — default for every surgical patient; start before induction and continue until ambulatory.
  • Graduated compression stockings (GCS) — less evidence than IPC for VTE reduction; avoid in severe peripheral arterial disease.
  • Mechanical alone is inadequate for moderate-to-high-risk patients; pair with chemical prophylaxis unless contraindicated.

Chronic Anticoagulation — Bridging and Periprocedural Management​

Warfarin​

Do not bridge routinely. The 2015 BRIDGE trial (atrial fibrillation, mean CHADS₂ 2.3) showed that forgoing bridging was non-inferior for thromboembolism (0.4% vs 0.3%) and reduced major bleeding (1.3% vs 3.2%).[4] The PERIOP2 trial extended the same conclusion to most mechanical valve patients.[5]

When to bridge (the shrinking list):

  • Mechanical mitral valve
  • Caged-ball aortic valve
  • Mechanical valve + atrial fibrillation
  • Recent (<3 months) VTE
  • Known severe thrombophilia with prior VTE

Warfarin hold timing:

  • Stop warfarin 5 days preoperatively; check INR day before surgery.
  • If INR >1.5 on the day of surgery: 1–2 mg oral vitamin K the evening before.
  • Restart warfarin 12–24 h postoperatively once hemostasis secure.

Direct Oral Anticoagulants (DOACs)​

DOACs have largely obviated bridging by virtue of their short half-lives. Procedure-specific hold times:[6]

AgentLow-bleeding-risk procedureHigh-bleeding-risk procedure
Apixaban, rivaroxaban, edoxaban24 h48 h
Dabigatran (CrCl ≥50)24 h48 h
Dabigatran (CrCl 30–49)48 h72 h

Resume ≥24 h (low-bleed) to ≥48–72 h (high-bleed) postoperatively.

Antiplatelet Therapy​

Aspirin:

  • Continue for secondary prevention for most urologic surgery — stopping aspirin increases perioperative MACE without proportional bleeding benefit.[7]
  • Hold 7 days for procedures with catastrophic-bleed-site risk (intracranial, posterior chamber ophthalmologic).
  • Primary prevention: stop 7 days before surgery.

P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor):

  • Timing depends on the stent indication and elapsed time since PCI.
  • Do not stop DAPT in the high-risk window without cardiology consultation:
    • Drug-eluting stent: continue DAPT for at least 3–6 months (contemporary stents) to 12 months (older protocols).
    • Bare-metal stent: continue DAPT for at least 4–6 weeks.
    • Prior ACS: continue DAPT for 12 months.
  • After the obligatory window, hold clopidogrel 5–7 days, ticagrelor 5 days, prasugrel 7 days.
  • Continue aspirin through the operation whenever feasible, even when stopping P2Y12.

Reversal of Antithrombotic Agents​

Warfarin​

  • 4-factor PCC (Kcentra) — first line for urgent reversal.
  • Vitamin K 5–10 mg IV — always given with PCC; onset 6–12 h.
  • FFP — slow onset, volume-heavy; reserve for PCC unavailability.

Direct Oral Anticoagulants​

  • Dabigatran — idarucizumab (Praxbind) 5 g IV (2 × 2.5 g doses).
  • Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) — 4-factor PCC (25–50 U/kg or fixed 2,000 U) is now first-line in the US following andexanet alfa's withdrawal from the US market (FDA accelerated-approval not converted to traditional approval; thrombotic-event and heparin-resistance safety concerns). See Anticoagulation reversal for mechanism and ANNEXA data.
  • Tranexamic acid — adjunct in major bleeding.

Heparin​

  • Protamine sulfate — 1 mg neutralizes ~100 U UFH; LMWH partial reversal only.

Antiplatelets​

  • No validated reversal agent for aspirin, clopidogrel, prasugrel, or ticagrelor.
  • Platelet transfusion — of limited benefit for chronic antiplatelet use and may be harmful in acute ischemic stroke (PATCH trial).[8]
  • Desmopressin (DDAVP) 0.3 μg/kg — may partially reverse platelet dysfunction in selected cases.

Heparin-Induced Thrombocytopenia (HIT)​

Suspect HIT in any patient with platelet drop of >50% between days 5–14 of heparin exposure (earlier if prior heparin exposure within 100 days) and new thrombosis or necrotic skin lesion at an injection site.

  • Stop all heparin (including flushes, LMWH, and heparin-bonded catheters).
  • Start non-heparin anticoagulant — argatroban or bivalirudin; transition to DOAC or warfarin only once platelets recover.
  • Confirm with PF4-heparin ELISA and serotonin release assay.

Heparin Resistance and Antithrombin Concentrate​

For the reconstructive urologist, heparin resistance appears in two specific settings: complex IVC thrombectomy / caval reconstruction on cardiopulmonary bypass, and rarely in the ICU after major pelvic oncology with sepsis-associated DIC. Both scenarios turn on antithrombin (AT) activity — heparin's anticoagulant effect is entirely mediated by potentiating AT, so insufficient AT produces apparent heparin resistance.[9]

Indications for AT Concentrate​

FDA-approved (THROMBATE III, plasma-derived):[10]

  • Hereditary antithrombin deficiency — the most clinically important inherited thrombophilia, with ≥50% lifetime VTE risk and 3–7× the VTE risk of other thrombophilias. Prevalence 1 in 2,000–5,000; functional AT typically 40–60% of normal.[11][12]
  • Short-term thromboprophylaxis in hereditary AT-deficient patients undergoing surgery, trauma, pregnancy, or labor.

Off-label:[9][13]

  • Heparin resistance on CPB / ECMO — the urologic-relevance indication.
  • Sepsis-associated DIC (controversial — see below).
  • Asparaginase-induced acquired AT deficiency in ALL.
  • Neonatal cardiac surgery (newborn AT is physiologically 20–80% of adult).

Dosing (Hereditary Deficiency)​

Loading dose formula:[10]

Units = (target AT% − baseline AT%) × weight (kg) / 1.4
  • Target AT level post-dose: 120% of normal.
  • Expected recovery: 1.4% increase per IU/kg.
  • Example: 70 kg patient, baseline AT 57% → dose = (120 − 57) × 70 / 1.4 = 3,150 IU.

Monitoring: baseline → 20 min post-infusion (peak) → 12 h later (trough).

Maintenance: 60% of the loading dose every 24 h. Target trough AT 80–120%. Duration 2–8 days depending on indication.

High-consumption states (surgery, hemorrhage, active thrombosis, concurrent heparin): AT half-life shortens; monitor more frequently and adjust.

Pharmacokinetics​

  • Half-life: 2.5–3.8 days (functional assay); mean 50% disappearance ~22 h.[10]
  • Recovery: 1.4%/IU/kg for plasma-derived.
  • Recombinant AT (goat-milk-derived Atryn, or CHO-cell-derived rhAT-gamma) has altered glycosylation with higher heparin affinity but shorter half-life, typically requiring continuous infusion.[14][15]

Sepsis-Associated DIC — the Ongoing Controversy​

Evidence remains split. A large phase III trial failed to show mortality benefit in general sepsis; post-hoc analyses and Japanese cohort data suggest benefit specifically in sepsis with overt DIC when heparin is not co-administered.[16][17][18] Recent meta-analysis showed improved DIC resolution (OR 5.21) without 28-day mortality benefit and without increased bleeding.[19]

Dosing in sepsis-DIC (Japanese studies):[20]

  • 3,000 IU/day × 3 days in patients with AT activity <40–50% — superior DIC resolution (66.7% vs 45.2%) and survival (77.1% vs 56.4%) vs 1,500 IU/day without increased bleeding.

Safety​

  • Most common adverse events: dizziness, chest tightness, nausea, fever, hives. Decrease rate or pause infusion until resolution.[10]
  • Bleeding risk: meta-analysis in critically ill patients showed RR 1.58 for bleeding (95% CI 1.35–1.84) — drive home the point that AT concentrate is not innocuous.[21]
  • Concurrent heparin requires dose reduction to avoid bleeding.
  • Plasma-derived products are heat-treated (60°C ≥10 h) for viral inactivation; theoretical transmission risk remains.

Retrospective Urologic-Relevant Evidence​

In cardiopulmonary bypass patients with suspected heparin resistance, AT concentrate was associated with a 66% reduction in mortality (OR 0.34) vs FFP in one retrospective analysis.[22] No randomized trials have directly compared AT concentrate with FFP for heparin resistance treatment.[23]

Practical Perioperative Checklist​

For every urologic surgical patient on antithrombotic therapy:

  1. Indication audit — why is the patient on this drug, how long have they been on it, and what is the underlying risk?
  2. Caprini score — document on the chart.
  3. Procedure bleeding risk from the Tikkinen matrix.
  4. Neuraxial plan — coordinate hold timing with anesthesia.
  5. Bridging decision — in the shrinking list of indications for which it is warranted, not by default.
  6. DAPT / stent history — cardiology consult before holding P2Y12 within the high-risk window.
  7. Restart plan — mechanical postop from induction, chemical prophylaxis at 12–24 h, therapeutic anticoagulation when hemostasis is secure.
  8. Extended prophylaxis — 28 days after pelvic cancer surgery.
  9. Reversal plan — 4F-PCC and idarucizumab availability confirmed before high-risk cases on anticoagulation. Andexanet is no longer available in the US; 4F-PCC is first-line for FXa inhibitor reversal.
  10. Thrombophilia history — hereditary AT deficiency is rare but catastrophically under-recognized; a patient with multiple VTEs in a young first-degree relative warrants hematology consultation and a plan for AT concentrate cover during high-risk surgery.

Pharmacology Hub Companions​

For drug-class pharmacology — agent-by-agent mechanism, dose, evidence, and safety detail — see the two companion hubs:

TopicWhere it lives
Workflow: procedure-specific bleed-vs-thrombosis weighing, DOAC hold timing, bridging, antiplatelet management, HIT, heparin resistance, AT concentrateThis article
Drug-class pharmacology of enoxaparin, UFH, apixaban, rivaroxaban, IPC; Caprini score; Westerman 2022 apixaban data; 4-week extended-prophylaxis evidencePharmacology: VTE prophylaxis
Drug-class pharmacology of idarucizumab, 4F-PCC, vitamin K, protamine; andexanet US withdrawal; ciraparantag pipelinePharmacology: Anticoagulation reversal

References​

1. Tikkinen KAO, Craigie S, Agarwal A, et al. "Procedure-Specific Risks of Thrombosis and Bleeding in Urological Non-Cancer Surgery: Systematic Review and Meta-Analysis." Eur Urol. 2018;73(2):236–241. doi:10.1016/j.eururo.2017.02.025

2. Forrest JB, Clemens JQ, Finamore P, et al. "AUA Best Practice Statement for the Prevention of Deep Vein Thrombosis in Patients Undergoing Urologic Surgery." American Urological Association; 2020.

3. Gould MK, Garcia DA, Wren SM, et al. "Prevention of VTE in Nonorthopedic Surgical Patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: ACCP Guidelines." Chest. 2012;141(2 Suppl):e227S–e277S. doi:10.1378/chest.11-2297

4. Douketis JD, Spyropoulos AC, Kaatz S, et al. "Perioperative Bridging Anticoagulation in Patients With Atrial Fibrillation." N Engl J Med. 2015;373(9):823–833. doi:10.1056/NEJMoa1501035

5. Kovacs MJ, Wells PS, Anderson DR, et al. "Postoperative Low Molecular Weight Heparin Bridging Treatment for Patients at High Risk of Arterial Thromboembolism (PERIOP2): Randomised Double-Blind Controlled Trial." BMJ. 2021;373:n1205. doi:10.1136/bmj.n1205

6. Douketis JD, Spyropoulos AC, Murad MH, et al. "Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline." Chest. 2022;162(5):e207–e243. doi:10.1016/j.chest.2022.07.025

7. Devereaux PJ, Mrkobrada M, Sessler DI, et al. "Aspirin in Patients Undergoing Noncardiac Surgery (POISE-2)." N Engl J Med. 2014;370(16):1494–1503. doi:10.1056/NEJMoa1401105

8. Baharoglu MI, Cordonnier C, Al-Shahi Salman R, et al. "Platelet Transfusion Versus Standard Care After Acute Stroke Due to Spontaneous Cerebral Haemorrhage Associated With Antiplatelet Therapy (PATCH)." Lancet. 2016;387(10038):2605–2613. doi:10.1016/S0140-6736(16)30392-0

9. Levy JH, Connors JM. "Heparin Resistance — Clinical Perspectives and Management Strategies." N Engl J Med. 2021;385(9):826–832. doi:10.1056/NEJMra2104091

10. US Food and Drug Administration. THROMBATE III Package Insert. Updated 2010.

11. Maclean PS, Tait RC. "Hereditary and Acquired Antithrombin Deficiency: Epidemiology, Pathogenesis and Treatment Options." Drugs. 2007;67(10):1429–40. doi:10.2165/00003495-200767100-00005

12. Bauer KA, Nguyen-Cao TM, Spears JB. "Issues in the Diagnosis and Management of Hereditary Antithrombin Deficiency." Ann Pharmacother. 2016;50(9):758–67. doi:10.1177/1060028016651276

13. Rodgers GM. "Role of Antithrombin Concentrate in Treatment of Hereditary Antithrombin Deficiency — An Update." Thromb Haemost. 2009;101(5):806–12.

14. Edmunds T, Van Patten SM, Pollock J, et al. "Transgenically Produced Human Antithrombin: Structural and Functional Comparison to Human Plasma-Derived Antithrombin." Blood. 1998;91(12):4561–71.

15. Pal N, Kertai MD, Lakshminarasimhachar A, Avidan MS. "Pharmacology and Clinical Applications of Human Recombinant Antithrombin." Expert Opin Biol Ther. 2010;10(7):1155–68. doi:10.1517/14712598.2010.495713

16. Key NS, Negrier C. "Coagulation Factor Concentrates: Past, Present, and Future." Lancet. 2007;370(9585):439–48. doi:10.1016/S0140-6736(07)61199-4

17. Wiedermann CJ. "Antithrombin Concentrate Use in Disseminated Intravascular Coagulation of Sepsis: Meta-Analyses Revisited." J Thromb Haemost. 2018;16(3):455–457. doi:10.1111/jth.13950

18. Tagami T. "Antithrombin Concentrate Use in Sepsis-Associated Disseminated Intravascular Coagulation." J Thromb Haemost. 2018;16(3):458–461. doi:10.1111/jth.13948

19. Li W, Sheng S, Zhu F. "Efficacy and Safety of Antithrombin or Recombinant Human Thrombomodulin in the Treatment of Disseminated Intravascular Coagulation: A Systematic Review and Meta-Analysis." Thromb Res. 2025;249:109302. doi:10.1016/j.thromres.2025.109302

20. Iba T, Saitoh D, Wada H, Asakura H. "Efficacy and Bleeding Risk of Antithrombin Supplementation in Septic Disseminated Intravascular Coagulation: A Secondary Survey." Crit Care. 2014;18(5):497. doi:10.1186/s13054-014-0497-x

21. Allingstrup M, Wetterslev J, Ravn FB, Møller AM, Afshari A. "Antithrombin III for Critically Ill Patients." Cochrane Database Syst Rev. 2016;2:CD005370. doi:10.1002/14651858.CD005370.pub3

22. Bader SO, Marinaro XF, Stone G, et al. "Antithrombin Concentrates May Benefit Cardiopulmonary Bypass Patients With Suspected Heparin Resistance: A Retrospective Analysis of Real-World Data." Heliyon. 2023;9(9):e19497. doi:10.1016/j.heliyon.2023.e19497

23. Spiess BD. "Treating Heparin Resistance With Antithrombin or Fresh Frozen Plasma." Ann Thorac Surg. 2008;85(6):2153–60. doi:10.1016/j.athoracsur.2008.02.037